What Happened?
Menlo Park, CA-based Phathom-Pharmaceuticals Appointed David Socks as Chief Executive Officer and Co founder
About the Company
Phathom Pharmaceuticals, launched in 2019 by Frazier Healthcare Partners and Takeda Pharmaceuticals, is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal (GI) diseases and disorders. The company is advancing the investigational agent vonoprazan, a novel potassium-competitive acid blocker (P-CAB). Vonoprazan has the potential to address multiple unmet needs among patients with gastroesophageal reflux disease (GERD) and other acid-related disorders.
About the Person
David Socks is Chief Executive Officer and Co founder at Phathom Pharmaceuticals. Previously, David held various senior HR leadership roles in the industry.
Info Source
News
Short Profile